Overview

A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors

Status:
Completed

Trial end date:
2020-01-31

Target enrollment:

Participant gender:

Summary

This trial is conducted in Africa, Asia, Europe and North America. The aim of the trial is to assess the efficacy of concizumab administered s.c. (subcutaneously, under the skin) once daily in preventing bleeding episodes in haemophilia A and B patients with inhibitors.

Phase:

Phase 2

Details

Lead Sponsor:

Novo Nordisk A/S

Treatments:

Factor VIII